Douglass Given, MD, PhD, MBA

Doug Given, MD, PhD, MBA, is a physician-scientist, executive, serial entrepreneur, and investor. Doug is an investor, member, owner and board advisor in Carlyle One Health Group LLC (COH). COH is an infectious diseases preparedness and biosecurity platform company focused on early warning systems, diagnostics, and next-generation vaccine technologies to commercially address global infectious disease threats. Doug serves as Board Chair and lead investor in Vivaldi Biosciences, Inc. Vivaldi develops genetically modified intranasal influenza vaccines designed for pandemic preparedness and global deployment. Doug is Managing Partner at Health2047 Capital Partners, an institutional healthcare venture capital firm, where he focuses on strategic healthcare investments and partnerships at the intersection of healthcare innovation, biotechnology and public health resilience. He founded, with the American Medical Association, Health2047 Inc., an integrated healthcare company formation firm, and served as its Chief Executive from 2015 to 2018. Doug previously spent more than two decades in venture capital as a General Partner at life sciences investor Bay City Capital, participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999 to 2015. Beginning in 1983, he was a global corporate and operating executive at Lilly, Monsanto, Schering Plough, and Mallinckrodt, and a serial entrepreneur. He led three public biopharmaceutical companies as CEO in addition to a number of private companies. Doug has served on more than 20 public and private company boards. He is currently Chairman of Visirna Inc. (Shanghai), Chairman of Vivaldi AG (Vienna), and serves as a Director of Health2047 Inc. and BrYet Health Ltd. He is Managing Partner at the G5 Partners LLC family office. He also served as Chairman of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) from 2010 to 2024. He serves in advisory roles on the University of Chicago Pritzker School of Medicine and Biological Sciences Division Council (former Chair), and on the Health Advisory Board, Johns Hopkins Bloomberg School of Public Health. He has served on the Harvard School of Public Health HIV/AIDS Initiative and International Council, the Stanford Medicine Community Council, and advisory boards for the Stanford Institute for Economic Policy Research (SIEPR), the Houston Methodist Research Institute, the Queensland Investment Corp. (Brisbane), and InnoMed Ventures. Doug received MD and PhD (Virology) degrees from the University of Chicago and an MBA from the Wharton School at the University of Pennsylvania. He was a Clinical and Research Fellow in Internal Medicine and Infectious Diseases at Massachusetts General Hospital and Harvard Medical School, and a Professor and Attending Physician at Indiana University School of Medicine.

Katie Given, MD, PhD, MBA

Dr. Given is a physician scientist and Mohs surgeon, founder and CEO of Given Dermatology Institute, a GenAI Medical Knowledge Expert contracting to Meta, and a clinical instructor of Mohs surgery at UCSF. Previously, she was part of Medical Group (Sutter Health) and also taught at the UCSF/SF VA hospitals. Board certified in Dermatology and Micrographic Surgery and Cutaneous Oncology (Mohs Surgery), she is board eligible in Clinical Informatics. A graduate of the University of Chicago and the Pritzker School of Medicine, Dr. Given completed her Dermatology residency at Yale-New Haven Hospitals, where she served as Chief Resident. She is board certified in Dermatology and Micrographic Surgery and Cutaneous Oncology (Mohs Surgery), and is board eligible in Clinical Informatics. Dr. Given received her PhD in Microbiology from the University of Chicago, Division of Biological Sciences, while performing BSL-3 select agent vaccine research and development in the Howard T Ricketts Laboratory, in partnership with the NIAID at Argonne National Laboratories. (The Ricketts Lab is one of 13 state-of-the-art level 3 biocontainment facilities conducting research and animal studies on biodefense-related and emerging infectious diseases.) Her work focused on Yersinia pestis vaccines (the causative agent of the Black Plague), the molecular and cellular mechanisms of plague pathogenesis, Staph aureus virulence genes as targets for vaccine development, anthrax virulence factors and other bacterial and viral pathogens. In addition, she was trained to certify the workforce in BSL-3 operations. While in training, she was awarded a T32 NIH Postdoctoral Fellowship in Clinical Informatics, and worked with a Melanoma Tumor Board Registry and the Yale New Haven Hospital Center for Outcomes Research and Evaluation (CORE) focusing on database quality and validation. She is actively engaged in further development of the MohsAIQ database with the American College of Mohs Surgery (ACMS). Dr. Given served as the Resident Representative to the Board of Directors for the ASDS/ASDSA (2019-2021) and is a Contributing Editor to the peer-reviewed journal Dermatologic Surgery. Dr. Given is an active member of AAD, ASDS, ACMS and the AMA. She also received her MBA in Managerial Organization and Entrepreneurship from the University of Chicago Booth School of Business. She worked as an Innovation Fellow through the Polsky Center at UChicago, supporting faculty new business and venture formation, and served as a graduate Teaching Assistant for Booth’s Commercializing Innovation curriculum. Since 2014, Dr. Given has served as a partner in G5 Partners LLC. She also serves a KOL and advisor for several device and imaging companies including PinPrint, Avita Medical, Enspectra, Retrouvé, and Portal Instruments. Dr. Given is an FAA-licensed pilot, with commercial, multi-engine and instrument ratings.